GIA
SRNE

Gladstone Institutional Advisory’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Gladstone Institutional Advisory’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-25,217
Closed -$158K – 305
2020
Q2 		$158K Buy
+25,217
New +$96.5K 0.04% 227

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Gladstone Institutional Advisory's SRNE Position: Q3 2020 in Review

Gladstone Institutional Advisory sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2020, closing a stake of 25,217 shares — an estimated $158K sold.

Gladstone Institutional Advisory first reported a position in SRNE in Q2 2020 and held it in 1 quarter. The position peaked at $158K in Q2 2020. 209 funds tracked by Wall St. Rank hold SRNE as of Q3 2020.

  • Gladstone Institutional Advisory reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • Gladstone Institutional Advisory sold 25,217 Sorrento Therapeutics, Inc. shares in Q3 2020, an estimated $158K.
  • Gladstone Institutional Advisory first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 1 quarter.
  • Gladstone Institutional Advisory's Sorrento Therapeutics, Inc. position peaked at $158K in Q2 2020.
  • 209 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2020.

Based on Gladstone Institutional Advisory's 13F filing for Q3 2020, filed 16 Nov 2020.